M Vaiani, M Cecchi, S Colombini, E Agostino, F Attanasio, M Ceroti, R Banfi.
Careggi Hospital, Pharmacy Department, Florence, Italy; 2ISPO, Molecular and Nutritional Epidemiology Unit, Florence, Italy
Background Recurrent glioblastoma is nearly always fatal, with median survival rates of approximately 12–14 months. Previous phase II clinical trials showed promising results with bevacizumab, alone or in combination with irinotecan, in patients with recurrent glioblastoma.
Purpose To assess whether the survival of patients with recurrent glioblastoma receiving bevacizumab alone or with irinotecan in everyday practise is comparable to that reported in clinical trials.
Materials and Methods This was a retrospective observational study conducted at a single hospital in Italy. Patients with recurrent glioblastoma who had received bevacizumab alone or with irinotecan from January 2009 to September 2011 were included in our study. The main outcome measures were progression-free survival (PFS), overall survival (OS), and rates of PFS and OS at 6 months.
Results Median PFS was 5.1 months in the bevacizumab group (n = 9) and 15.4 months in the bevacizumab + irinotecan group (n = 10), with 6-month PFS rates of 45% and 69%, respectively. Median OS was 6.8 months for bevacizumab alone and 11.1 months for bevacizumab + irinotecan, with 6-month OS rates of 100% and 90%, respectively.
Conclusions Although the number of patients included is not sufficient to allow a conclusive statement about the place of bevacizumab in the treatment of recurrent glioblastoma, the data appear promising, and are consistent with the results of clinical trials.
Reference Eur J Hosp Pharm 2013;20(Suppl 1):A1–238
Careggi Hospital, Pharmacy Department, Florence, Italy; 2ISPO, Molecular and Nutritional Epidemiology Unit, Florence, Italy
Background Recurrent glioblastoma is nearly always fatal, with median survival rates of approximately 12–14 months. Previous phase II clinical trials showed promising results with bevacizumab, alone or in combination with irinotecan, in patients with recurrent glioblastoma.
Purpose To assess whether the survival of patients with recurrent glioblastoma receiving bevacizumab alone or with irinotecan in everyday practise is comparable to that reported in clinical trials.
Materials and Methods This was a retrospective observational study conducted at a single hospital in Italy. Patients with recurrent glioblastoma who had received bevacizumab alone or with irinotecan from January 2009 to September 2011 were included in our study. The main outcome measures were progression-free survival (PFS), overall survival (OS), and rates of PFS and OS at 6 months.
Results Median PFS was 5.1 months in the bevacizumab group (n = 9) and 15.4 months in the bevacizumab + irinotecan group (n = 10), with 6-month PFS rates of 45% and 69%, respectively. Median OS was 6.8 months for bevacizumab alone and 11.1 months for bevacizumab + irinotecan, with 6-month OS rates of 100% and 90%, respectively.
Conclusions Although the number of patients included is not sufficient to allow a conclusive statement about the place of bevacizumab in the treatment of recurrent glioblastoma, the data appear promising, and are consistent with the results of clinical trials.
Reference Eur J Hosp Pharm 2013;20(Suppl 1):A1–238
Nenhum comentário:
Postar um comentário